Frankel Diane, Bourlard Donatienne, Garcia Stéphane, Robaglia-Schlupp Andrée, Peker Emel, Groliere Adèle, Kaspi Elise, Roll Patrice
Service de biologie cellulaire, hôpital la Timone, AP-HM, 13385 Marseille cedex 5, France; Inserm, MMG, Aix Marseille université, 13385 Marseille cedex 5, France.
Service de biologie cellulaire, hôpital la Timone, AP-HM, 13385 Marseille cedex 5, France.
Ann Pathol. 2019 Jun;39(3):227-236. doi: 10.1016/j.annpat.2018.12.003. Epub 2019 Jan 30.
The identification of ALK and ROS1 rearrangements has become essential for the theranostic management of patients with non-small cell lung cancer, especially in stage IV or inoperable patients. These testings are now performed by immunohistochemistry on histological samples and confirmed by fluorescent in situ hybridization in case of positive or doubtful results. The diagnosis of lung cancer is often performed at an advanced or metastatic stage and cytological sample could be the only material containing malignant cells available at these stages. Therefore, the detection of ALK and ROS1 rearrangement by immunocytochemical analysis on cytological specimens is needed. We performed this test on 27 cytological samples of lung adenocarcinomas, and we compared our results with several other techniques: on the same sample or on biopsy in another laboratory, on the same sample by fluorescent in situ hybridization and/or immunochemistry. We found a very good concordance between all these techniques, thus validating our immunocytochemical method on cytological samples according to the ISO 15189 norm.
ALK和ROS1重排的鉴定对于非小细胞肺癌患者的诊疗管理至关重要，尤其是对于IV期或无法手术的患者。目前，这些检测通过对组织学样本进行免疫组织化学来完成，若结果为阳性或存疑，则通过荧光原位杂交进行确认。肺癌诊断通常在晚期或转移期进行，而细胞学样本可能是这些阶段唯一可获得的含有恶性细胞的材料。因此，需要通过对细胞学标本进行免疫细胞化学分析来检测ALK和ROS1重排。我们对27例肺腺癌的细胞学样本进行了此项检测，并将我们的结果与其他几种技术进行了比较：在另一个实验室对同一样本或活检样本进行检测、通过荧光原位杂交和/或免疫化学对同一样本进行检测。我们发现所有这些技术之间具有很好的一致性，从而根据ISO 15189标准验证了我们在细胞学样本上的免疫细胞化学方法。
